NARDO, ANTONELLA
 Distribuzione geografica
Continente #
AS - Asia 160
NA - Nord America 101
EU - Europa 73
SA - Sud America 22
AF - Africa 13
Totale 369
Nazione #
US - Stati Uniti d'America 96
CN - Cina 69
SG - Singapore 59
IT - Italia 58
KR - Corea 24
BR - Brasile 19
CI - Costa d'Avorio 11
FI - Finlandia 5
IE - Irlanda 4
IN - India 3
MX - Messico 3
CA - Canada 2
GB - Regno Unito 2
BD - Bangladesh 1
BE - Belgio 1
CL - Cile 1
CZ - Repubblica Ceca 1
DE - Germania 1
EC - Ecuador 1
IQ - Iraq 1
OM - Oman 1
PK - Pakistan 1
PL - Polonia 1
SC - Seychelles 1
SN - Senegal 1
VE - Venezuela 1
VN - Vietnam 1
Totale 369
Città #
Hefei 48
Singapore 42
Santa Clara 36
Seoul 24
Chicago 15
Dallas 15
Abidjan 11
Civitanova Marche 8
Milan 7
Ashburn 6
Boardman 5
Los Angeles 5
Beijing 4
Catania 4
Dublin 4
Mexico City 3
Palermo 3
Rome 3
Tremestieri Etneo 3
Chennai 2
Florence 2
Helsinki 2
Lappeenranta 2
Aragona 1
Baghdad 1
Barueri 1
Belpasso 1
Brasília 1
Bronte 1
Brussels 1
Buffalo 1
Campinas 1
Campos do Jordão 1
Can Tho 1
Caucaia 1
Chongqing 1
Curitiba 1
Dakar 1
Dalian 1
Extrema 1
Fazenda Rio Grande 1
Fort St. James 1
Genoa 1
Guayaquil 1
Itaberaba 1
Itaquaquecetuba 1
Lahore 1
Langfang 1
Linyi 1
London 1
Manchester 1
Mariana 1
Messina 1
Munich 1
Naples 1
New York 1
Newmarket 1
Olomouc 1
Passa e Fica 1
Phoenix 1
Pirenópolis 1
Rancagua 1
Registro 1
Rio de Janeiro 1
Santa Maria 1
Santos 1
Seeb 1
São Paulo 1
Sítio Novo do Tocantins 1
Turku 1
Valencia 1
Warsaw 1
Washington 1
Totale 304
Nome #
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 66
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting 62
AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib 58
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 54
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 51
Emergencies in Hematology: Why, When and How I Treat? 39
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 26
Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point? 22
Totale 378
Categoria #
all - tutte 1.636
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.636


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202317 0 0 0 0 0 0 4 2 4 0 7 0
2023/202456 0 4 2 9 0 14 10 1 0 3 12 1
2024/2025183 1 24 5 14 25 26 8 5 12 15 25 23
2025/2026122 41 81 0 0 0 0 0 0 0 0 0 0
Totale 378